What genetic mutations are commonly found in Breast Cancer

Common Genetic Mutations in Breast Cancer

Genetic mutations in breast cancer fall into two important categories: inherited mutations (germline) that you're born with, and acquired mutations (somatic) that develop in the tumor itself. Let me explain both.

INHERITED MUTATIONS (Germline)

These are mutations passed down from your parents. According to NCCN Guidelines, about 1 in 10 breast cancers are hereditary.

BRCA1 and BRCA2 (Most Common)

These are the best-known breast cancer genes. Normal BRCA genes act like "repair workers" for damaged DNA. When mutated:

• BRCA1 and BRCA2 mutations significantly increase breast cancer risk
• They also increase risk for ovarian, prostate, pancreatic, and melanoma skin cancers
• These mutations can be passed to your children
• Mutated BRCA genes can also affect how well certain treatments work

Other Inherited Genes

According to NCCN Guidelines, several other genes can increase breast cancer risk:

• PALB2 - partners with BRCA2 to repair DNA
• ATM - helps regulate DNA damage response
• CHEK2 - involved in DNA damage checkpoints
• TP53 - a major tumor suppressor gene
• MLH1, MSH2, MSH6, PMS2 - mismatch repair genes (also linked to Lynch syndrome)

ACQUIRED MUTATIONS (Somatic - In the Tumor)

These mutations develop only in cancer cells, not in your whole body. According to NCCN Guidelines for Metastatic Breast Cancer, doctors test for several important tumor mutations:

Hormone Receptor Status

• ER (Estrogen Receptor) - positive or negative
• PR (Progesterone Receptor) - positive or negative
• These indicate whether the cancer uses hormones to grow

HER2 Status

• HER2 (Human Epidermal Growth Factor Receptor 2) - amplified/overexpressed or negative
• This is crucial because HER2-positive cancers respond to targeted therapies like trastuzumab (Herceptin)

Other Actionable Tumor Mutations

According to NCCN Guidelines, testing may identify:

• PIK3CA mutations - can be targeted with specific therapies
• AKT1 mutations - potential treatment targets
• PTEN mutations - involved in cell growth pathways
• ESR1 mutations - found in hormone receptor-positive tumors
• NTRK mutations - can be targeted with specific drugs
• RET mutations - potential treatment targets

WHY THIS MATTERS FOR YOUR CARE

For inherited mutations: If you have a BRCA1/2 or other inherited mutation, this information helps your doctors:

• Choose the most effective treatments (some drugs work better with certain mutations)
• Screen you for other cancers
• Recommend genetic counseling for family members

For tumor mutations: These guide treatment selection. For example:

• HER2-positive cancers are treated differently than HER2-negative
• Hormone receptor status determines if hormone therapy is an option
• Specific mutations may predict response to targeted therapies or immunotherapy

IMPORTANT QUESTIONS TO ASK YOUR DOCTOR

1. Have I been tested for inherited BRCA1/2 mutations? (NCCN recommends this for all metastatic breast cancer patients)
2. What are my tumor's hormone receptor and HER2 status?
3. Were additional biomarkers tested on my tumor? (like PIK3CA, ESR1, NTRK, or RET)
4. How do my specific mutations affect my treatment options?
5. Should my family members be tested for inherited mutations?
6. Are there clinical trials available for my specific mutation profile?

KEY TAKEAWAY

Understanding your specific mutations—both inherited and in your tumor—is essential for personalized treatment planning. Your oncology team uses this information to select therapies most likely to work for your cancer.

---

Sources:

• NCCN Guidelines for Patients: Metastatic Breast Cancer (2024)
• NCCN Guidelines for Breast Cancer (current version)
• American Cancer Society recommendations on genetic testing

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.